{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:09:35Z","timestamp":1782446975580,"version":"3.54.5"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12029-024-01111-w","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:30:51Z","timestamp":1726025451000},"page":"1498-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of Interleukins in Pancreatic Cancer: A Literature Review"],"prefix":"10.1007","volume":"55","author":[{"given":"Saira","family":"Rafaqat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Khurshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Hafeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehnaz","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahrukh","family":"Gilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Rafaqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"1111_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cgt.2016.65","volume":"24","author":"M Pergamo","year":"2017","unstructured":"Pergamo M, Miller G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther. 2017;24:100\u20135.","journal-title":"Cancer Gene Ther"},{"key":"1111_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1111_CR3","doi-asserted-by":"publisher","first-page":"8962321","DOI":"10.1155\/2016\/8962321","volume":"2016","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Zeng L, Chen Y, et al. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016;2016:8962321.","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"1111_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"1111_CR5","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.7314\/APJCP.2015.16.14.5619","volume":"16","author":"V Goral","year":"2015","unstructured":"Goral V. Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev. 2015;16(14):5619\u201324.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1111_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajpath.2018.10.004","volume":"189","author":"B Ren","year":"2019","unstructured":"Ren B, Liu X, Suriawinata AA. Pancreatic ductal adenocarcinoma and its precursor lesions: histopathology, cytopathology, and molecular pathology. Am J Pathol. 2019;189(1):9\u201321.","journal-title":"Am J Pathol"},{"issue":"5","key":"1111_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"9","key":"1111_CR8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3748\/wjg.v20.i9.2237","volume":"20","author":"AA Rucki","year":"2014","unstructured":"Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol: WJG. 2014;20(9):2237.","journal-title":"World J Gastroenterol: WJG"},{"issue":"3","key":"1111_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"issue":"1","key":"1111_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/sj.bjc.6605107","volume":"101","author":"D \u00d6hlund","year":"2009","unstructured":"\u00d6hlund D, Lundin C, Ardnor B, \u00d6man M, Naredi P, Sund M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer. 2009;101(1):91\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"1111_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1042\/BJ20111240","volume":"441","author":"MA Shields","year":"2012","unstructured":"Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochemical Journal. 2012;441(2):541\u201352.","journal-title":"Biochemical Journal"},{"issue":"10","key":"1111_CR12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168\u201378.","journal-title":"Nat Genet"},{"issue":"5933","key":"1111_CR13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457\u201361.","journal-title":"Science"},{"issue":"8","key":"1111_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1111_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2011.12.021","volume":"148","author":"DA Tuveson","year":"2012","unstructured":"Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148(1):21\u20133.","journal-title":"Cell"},{"issue":"492","key":"1111_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2020.07.041","volume":"1","author":"VM Shah","year":"2020","unstructured":"Shah VM, Sheppard BC, Sears RC, Alani AW. Hypoxia: friend or Foe for drug delivery in Pancreatic Cancer. Cancer Lett. 2020;1(492):63\u201370.","journal-title":"Cancer Lett"},{"issue":"1","key":"1111_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2012","unstructured":"Keith B, Johnson RS, Simon MC. HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"7586","key":"1111_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massagu\u00e9","year":"2016","unstructured":"Massagu\u00e9 J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298\u2013306.","journal-title":"Nature"},{"issue":"1","key":"1111_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12024","volume":"11","author":"J Massagu\u00e9","year":"2017","unstructured":"Massagu\u00e9 J, Batlle E, Gomis RR. Understanding the molecular mechanisms driving metastasis. Mol Oncol. 2017;11(1):3.","journal-title":"Mol Oncol"},{"issue":"26","key":"1111_CR20","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"10018","key":"1111_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. The Lancet. 2016;387(10018):545\u201357.","journal-title":"The Lancet"},{"issue":"6382","key":"1111_CR22","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.359.6382.1344","volume":"359","author":"PN Kelly","year":"2018","unstructured":"Kelly PN. The cancer immunotherapy revolution. Science. 2018;359(6382):1344\u20135.","journal-title":"Science"},{"key":"1111_CR23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"1111_CR24","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"issue":"13","key":"1111_CR25","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.12998\/wjcc.v9.i13.2969","volume":"9","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Jung YJ, Moon SH. Immunotherapy for pancreatic cancer. World J Clin Cases. 2021;9(13):2969\u201382.","journal-title":"World J Clin Cases"},{"issue":"6","key":"1111_CR26","doi-asserted-by":"publisher","first-page":"e13107","DOI":"10.1111\/sji.13107","volume":"94","author":"V Sharma","year":"2021","unstructured":"Sharma V, Sachdeva N, Gupta V, Nada R, Jacob J, Sahni D, Aggarwal A. IL-6 is associated with expansion of myeloid-derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients. Scand J Immunol. 2021;94(6):e13107.","journal-title":"Scand J Immunol"},{"issue":"10","key":"1111_CR27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.190.10.1367","volume":"190","author":"C Cordon-Cardo","year":"1999","unstructured":"Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med. 1999;190(10):1367\u201370.","journal-title":"J Exp Med"},{"key":"1111_CR28","doi-asserted-by":"publisher","first-page":"850093","DOI":"10.3389\/fimmu.2022.850093","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Wang J, Wang H, et al. The interplay between inflammation and stromal components in pancreatic cancer. Front Immunol. 2022;13:850093.","journal-title":"Front Immunol"},{"issue":"8","key":"1111_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","volume":"21","author":"D Briukhovetska","year":"2021","unstructured":"Briukhovetska D, D\u00f6rr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21(8):481\u201399.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1111_CR30","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1177\/0300060518800588","volume":"46","author":"L Feng","year":"2018","unstructured":"Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z, et al. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res. 2018;46(12):5228\u201336.","journal-title":"J Int Med Res"},{"key":"1111_CR31","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499\u2013506.","journal-title":"J Immunol"},{"key":"1111_CR32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/2159-8290.CD-15-0947","volume":"6","author":"M Waghray","year":"2016","unstructured":"Waghray M, Yalamanchili M, Dziubinski M, et al. GM-CSF mediates mesenchymal-epithelial cross-talk in pancreatic cancer. Cancer Discov. 2016;6:886\u201399.","journal-title":"Cancer Discov"},{"key":"1111_CR33","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3892\/ijo.2016.3374","volume":"48","author":"K Horioka","year":"2016","unstructured":"Horioka K, Ohuchida K, Sada M, et al. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. Int J Oncol. 2016;48:1499\u2013508.","journal-title":"Int J Oncol"},{"key":"1111_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2014.08.007","volume":"355","author":"S Deng","year":"2014","unstructured":"Deng S, Zhu S, Wang B, et al. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial\u2013mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Cancer Lett. 2014;355:184\u201391.","journal-title":"Cancer Lett"},{"key":"1111_CR35","first-page":"1","volume":"20","author":"HK Lee","year":"2024","unstructured":"Lee HK, Kim SY, Chung SH, Choi B, Kim JE, Yoon D, Jang SI, Yeo A, Kang HG, Lee J, Choi YH. Tumour-associated myeloid cells expressing IL-10R2\/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma. Br J Cancer. 2024;20:1\u20131.","journal-title":"Br J Cancer"},{"issue":"8","key":"1111_CR36","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/0008-5472.CAN-23-1200","volume":"84","author":"SP Singh","year":"2024","unstructured":"Singh SP, Dosch AR, Mehra S, De Castro SI, Bianchi A, Garrido VT, Zhou Z, Adams A, Amirian H, Box EW, Sun X. Tumor cell\u2013intrinsic p38 MAPK signaling promotes IL1\u03b1-mediated stromal inflammation and therapeutic resistance in pancreatic cancer. Can Res. 2024;84(8):1320\u201332.","journal-title":"Can Res"},{"issue":"5","key":"1111_CR37","doi-asserted-by":"publisher","first-page":"e97613","DOI":"10.1371\/journal.pone.0097613","volume":"9","author":"W B\u0142ogowski","year":"2014","unstructured":"B\u0142ogowski W, Deskur A, Budkowska M, Sa\u0142ata D, Madej-Michniewicz A, D\u0105bkowski K, Do\u0142\u0119gowska B, Starzy\u0144ska T. Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS ONE. 2014;9(5):e97613.","journal-title":"PLoS ONE"},{"issue":"2","key":"1111_CR38","doi-asserted-by":"publisher","first-page":"e1388485","DOI":"10.1080\/2162402X.2017.1388485","volume":"7","author":"I Siddiqui","year":"2018","unstructured":"Siddiqui I, Erreni M, Kamal MA, et al. Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. Oncoimmunology. 2018;7(2):e1388485.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1111_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13578-023-01090-8","volume":"13","author":"YC Fan","year":"2023","unstructured":"Fan YC, Fong YC, Kuo CT, et al. Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer. Cell Biosci. 2023;13(1):147.","journal-title":"Cell Biosci"},{"issue":"4","key":"1111_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/172460080502000406","volume":"20","author":"E Greco","year":"2005","unstructured":"Greco E, Basso D, Fogar P, et al. Pancreatic cancer cells invasiveness is mainly affected by interleukin-1\u03b2 not by transforming growth factor-\u03b21. Int J Biol Markers. 2005;20(4):235\u201341.","journal-title":"Int J Biol Markers"},{"issue":"8","key":"1111_CR41","doi-asserted-by":"publisher","first-page":"e70874","DOI":"10.1371\/journal.pone.0070874","volume":"8","author":"V Tjomsland","year":"2013","unstructured":"Tjomsland V, Bojmar L, Sandstr\u00f6m P, et al. IL-1\u03b1 expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway. PLoS ONE. 2013;8(8):e70874.","journal-title":"PLoS ONE"},{"issue":"8","key":"1111_CR42","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1593\/neo.11332","volume":"13","author":"V Tjomsland","year":"2011","unstructured":"Tjomsland V, Sp\u00e5ngeus A, V\u00e4lil\u00e4 J, et al. Interleukin 1\u03b1 sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia. 2011;13(8):664\u201375.","journal-title":"Neoplasia"},{"key":"1111_CR43","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.neo.2022.100789","volume":"28","author":"KM Herremans","year":"2022","unstructured":"Herremans KM, Szymkiewicz DD, Riner AN, et al. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Neoplasia. 2022;28:100789.","journal-title":"Neoplasia"},{"key":"1111_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF02592575","volume":"25","author":"D Basso","year":"1995","unstructured":"Basso D, Plebani M, Fogar P, et al. Insulin-like growth factor-I, interleukin-1 \u03b1 and \u03b2 in pancreatic cancer: role in tumor invasiveness and associated diabetes. Int J Clin Lab Res. 1995;25:40\u20133.","journal-title":"Int J Clin Lab Res"},{"issue":"11","key":"1111_CR45","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1054\/bjoc.2000.1479","volume":"83","author":"MD Barber","year":"2000","unstructured":"Barber MD, Powell JJ, Lynch SF, et al. A polymorphism of the interleukin-1 \u03b2 gene influences survival in pancreatic cancer. Br J Cancer. 2000;83(11):1443\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"1111_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","volume":"15","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen X, Wang H, et al. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. J Hematol Oncol. 2022;15(1):1\u20135.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1111_CR47","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das S, Shapiro B, Vucic EA, Vogt S, Bar-Sagi D. Tumor cell\u2013derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 2020;80(5):1088\u2013101.","journal-title":"Cancer Res"},{"key":"1111_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0521-4","volume":"7","author":"E Brunetto","year":"2019","unstructured":"Brunetto E, De Monte L, Balzano G, et al. The IL-1\/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J Immunother Cancer. 2019;7:1\u20133.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1111_CR49","first-page":"137","volume":"26","author":"R Pezzilli","year":"1994","unstructured":"Pezzilli R, Billi P, Beltrandi E, et al. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis. Ital J Gastroenterol. 1994;26(3):137\u201340.","journal-title":"Ital J Gastroenterol"},{"issue":"2","key":"1111_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0304-3835(98)00259-6","volume":"134","author":"F Gansauge","year":"1998","unstructured":"Gansauge F, Steinbach G, Gansauge S, et al. Prognostic significance of soluble interleukin-2 receptor-\u03b1 in adenocarcinoma of the pancreas. Cancer Lett. 1998;134(2):193\u20139.","journal-title":"Cancer Lett"},{"issue":"67","key":"1111_CR51","first-page":"141","volume":"53","author":"C Angelini","year":"2006","unstructured":"Angelini C, Bovo G, Muselli P, et al. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results. Hepatogastroenterology. 2006;53(67):141\u20134.","journal-title":"Hepatogastroenterology"},{"issue":"8","key":"1111_CR52","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1073\/pnas.93.8.3669","volume":"93","author":"BA Pulaski","year":"1996","unstructured":"Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex \u201cre-presentation\u201d of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci. 1996;93(8):3669\u201374.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"1111_CR53","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/0016-5085(91)70022-P","volume":"100","author":"WG Dippold","year":"1991","unstructured":"Dippold WG, Klingel R, Kerlin M, Schwaeble W, Zum B\u00fcschenfelde KH. Stimulation of pancreas and gastric carcinoma cell growth by interleukin 3 and granulocyte-macrophage colony\u2014stimulating factor. Gastroenterology. 1991;100(5):1338\u201344.","journal-title":"Gastroenterology"},{"issue":"3","key":"1111_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5301\/JBM.2012.9348","volume":"27","author":"G Vasiliades","year":"2012","unstructured":"Vasiliades G, Kopanakis N, Vasiloglou M, Zografos G, Margaris H, Masselou K, Kokosi E, Liakakos T. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers. 2012;27(3):186\u201394.","journal-title":"Int J Biol Markers"},{"issue":"2","key":"1111_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1515\/CCLM.2005.024","volume":"43","author":"B Mroczko","year":"2005","unstructured":"Mroczko B, Szmitkowski M, Wereszczy\u0144ska-Siemiatkowska U, Jurkowska G. Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clin Chem Lab Med. 2005;43(2):146\u201350.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"1111_CR56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cyto.2012.06.286","volume":"60","author":"A Schmieder","year":"2012","unstructured":"Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012;60(2):514\u201321.","journal-title":"Cytokine"},{"issue":"13","key":"1111_CR57","first-page":"3575","volume":"62","author":"K Kawakami","year":"2002","unstructured":"Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Can Res. 2002;62(13):3575\u201380.","journal-title":"Can Res"},{"issue":"1A","key":"1111_CR58","first-page":"125","volume":"19","author":"M Kornmann","year":"1999","unstructured":"Kornmann M, Kleeff J, Debinski W, Korc M. Pancreatic cancer cells express interleukin-13 and-4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and-4. Anticancer Res. 1999;19(1A):125\u201331.","journal-title":"Anticancer Res"},{"issue":"5","key":"1111_CR59","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/sj.bjc.6602416","volume":"92","author":"O Prokopchuk","year":"2005","unstructured":"Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer. 2005;92(5):921\u20138.","journal-title":"Br J Cancer"},{"issue":"6","key":"1111_CR60","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/ijms22062998","volume":"22","author":"J Shi","year":"2021","unstructured":"Shi J, Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021;22(6):2998.","journal-title":"Int J Mol Sci"},{"key":"1111_CR61","doi-asserted-by":"publisher","first-page":"10509","DOI":"10.1073\/pnas.180318697","volume":"97","author":"H Ochi","year":"2000","unstructured":"Ochi H, De Jesus NH, Hsieh FH, Austen KF, Boyce JA. IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. Proc Natl Acad Sci U S A. 2000;97:10509\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1111_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12964-020-00594-x","volume":"18","author":"SB Gitto","year":"2020","unstructured":"Gitto SB, Beardsley JM, Nakkina SP, et al. Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells. Cell Commun Signal. 2020;18(1):95.","journal-title":"Cell Commun Signal"},{"issue":"20","key":"1111_CR63","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1158\/0008-5472.CAN-13-1558-T","volume":"73","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yan W, Collins MA, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013;73(20):6359\u201374.","journal-title":"Cancer Res"},{"issue":"11","key":"1111_CR64","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41419-020-03168-4","volume":"11","author":"K Kesh","year":"2020","unstructured":"Kesh K, Garrido VT, Dosch A, et al. Stroma secreted IL6 selects for \u201cstem-like\u201d population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways. Cell Death Dis. 2020;11(11):967.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1111_CR65","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina M, Kurkowski MU, Ludes K, et al. Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456\u201369.","journal-title":"Cancer Cell"},{"issue":"14","key":"1111_CR66","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","volume":"71","author":"RB Corcoran","year":"2011","unstructured":"Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"1111_CR67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jjco\/28.1.12","volume":"28","author":"S Okada","year":"1998","unstructured":"Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998;28(1):12\u20135.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"1111_CR68","doi-asserted-by":"publisher","first-page":"e5926","DOI":"10.1097\/MD.0000000000005926","volume":"96","author":"HW Kim","year":"2017","unstructured":"Kim HW, Lee JC, Paik KH, Kang J, Kim J, Hwang JH. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine. 2017;96(5):e5926.","journal-title":"Medicine."},{"key":"1111_CR69","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/annonc\/mdz155.056","volume":"30","author":"V Pop","year":"2019","unstructured":"Pop V, Seicean A, Soritau O, Buiga R, Barsan M, Balacescu L, et al. Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer. Ann Oncol. 2019;30:iv15\u20136.","journal-title":"Ann Oncol"},{"issue":"4B","key":"1111_CR70","first-page":"3187","volume":"26","author":"R Bartsch","year":"2006","unstructured":"Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res. 2006;26(4B):3187\u201390.","journal-title":"Anticancer Res"},{"issue":"1","key":"1111_CR71","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.smim.2014.01.002","volume":"26","author":"M Lesina","year":"2014","unstructured":"Lesina M, W\u00f6rmann SM, Neuh\u00f6fer P, Song L, Alg\u00fcl H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol. 2014;26(1):80\u20137.","journal-title":"Semin Immunol"},{"issue":"7","key":"1111_CR72","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jcyt.2021.12.005","volume":"24","author":"R Antoon","year":"2022","unstructured":"Antoon R, Wang XH, Saleh AH, Warrington J, Hedley DW, Keating A. Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell\u2013derived IL-6 is reversed predominantly by IL-6 blockade. Cytotherapy. 2022;24(7):699\u2013710.","journal-title":"Cytotherapy"},{"issue":"28","key":"1111_CR73","doi-asserted-by":"publisher","first-page":"11143","DOI":"10.1074\/jbc.RA118.003276","volume":"293","author":"GL Razidlo","year":"2018","unstructured":"Razidlo GL, Burton KM, McNiven MA. Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem. 2018;293(28):11143\u201353.","journal-title":"J Biol Chem"},{"issue":"4","key":"1111_CR74","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1499-3872(14)60259-9","volume":"13","author":"R Holmer","year":"2014","unstructured":"Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13(4):371\u201380.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"24","key":"1111_CR75","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1002\/cam4.4823","volume":"11","author":"H Suzuki","year":"2022","unstructured":"Suzuki H, Mitsunaga S, Ikeda M, et al. Interleukin 6\/gp130 axis promotes neural invasion in pancreatic cancer. Cancer Med. 2022;11(24):5001\u201312.","journal-title":"Cancer Med"},{"issue":"40","key":"1111_CR76","doi-asserted-by":"publisher","first-page":"65982","DOI":"10.18632\/oncotarget.11786","volume":"7","author":"NS Nagathihalli","year":"2016","unstructured":"Nagathihalli NS, Castellanos JA, VanSaun MN, et al. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget. 2016;7(40):65982.","journal-title":"Oncotarget"},{"issue":"2","key":"1111_CR77","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/cancers15020456","volume":"15","author":"NA Hering","year":"2023","unstructured":"Hering NA, G\u00fcnzler E, Arndt M, et al. Targeting interleukin-6\/glycoprotein-130 signaling by raloxifene or SC144 enhances paclitaxel efficacy in pancreatic cancer. Cancers. 2023;15(2):456.","journal-title":"Cancers"},{"issue":"18","key":"1111_CR78","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.3390\/jcm10184157","volume":"10","author":"SH Heo","year":"2021","unstructured":"Heo SH, Jang SI, Kim SY, Choi B, Lee DK, Lee HK, et al. Characterization of circulating IL-7R positive cell populations for early detection of pancreatic ductal adenocarcinoma. J Clin Med. 2021;10(18):4157.","journal-title":"J Clin Med"},{"issue":"3","key":"1111_CR79","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cancers14030853","volume":"14","author":"SI Jang","year":"2022","unstructured":"Jang SI, Cho JH, Kim SY, et al. Validation of IL-7R as an immunological biomarker for human pancreatic ductal adenocarcinoma. Cancers (Basel). 2022;14(3):853.","journal-title":"Cancers (Basel)"},{"key":"1111_CR80","doi-asserted-by":"publisher","first-page":"215722","DOI":"10.1016\/j.canlet.2022.215722","volume":"539","author":"P Li","year":"2022","unstructured":"Li P, Rozich N, Wang J, et al. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Cancer Lett. 2022;539:215722.","journal-title":"Cancer Lett"},{"issue":"16","key":"1111_CR81","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.1158\/0008-5472.CAN-04-3858","volume":"65","author":"JG Trevino","year":"2005","unstructured":"Trevino JG, Summy JM, Gray MJ, et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 2005;65(16):7214\u201322.","journal-title":"Cancer Res"},{"issue":"4","key":"1111_CR82","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1349-7006.2008.00740.x","volume":"99","author":"M Li","year":"2008","unstructured":"Li M, Zhang Y, Feurino LW, et al. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci. 2008;99(4):733\u20137.","journal-title":"Cancer Sci"},{"issue":"10","key":"1111_CR83","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3748\/wjg.v18.i10.1123","volume":"18","author":"Y Chen","year":"2012","unstructured":"Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, et al. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 2012;18(10):1123\u20139.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"1111_CR84","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/jcm7120502","volume":"7","author":"YC Hou","year":"2018","unstructured":"Hou YC, Wang CJ, Chao YJ, et al. Elevated serum interleukin-8 level correlates with cancer-related cachexia and sarcopenia: an indicator for pancreatic cancer outcomes. J Clin Med. 2018;7(12):502.","journal-title":"J Clin Med"},{"issue":"1","key":"1111_CR85","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1038\/srep05911","volume":"4","author":"L Chen","year":"2014","unstructured":"Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, Liu L. The IL-8\/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014;4(1):5911.","journal-title":"Sci Rep"},{"issue":"11","key":"1111_CR86","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1089\/10799900050198372","volume":"20","author":"X Le","year":"2000","unstructured":"Le X, Shi Q, Wang B, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res. 2000;20(11):935\u201346.","journal-title":"J Interferon Cytokine Res"},{"key":"1111_CR87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s002620050503","volume":"47","author":"M Miyamoto","year":"1998","unstructured":"Miyamoto M, Shimizu Y, Okada K, Kashii Y, Higuchi K, Watanabe A. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother. 1998;47:47\u201357.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1111_CR88","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1039\/C3BM60325C","volume":"2","author":"G Lin","year":"2014","unstructured":"Lin G, Yang C, Hu R, et al. Interleukin-8 gene silencing on pancreatic cancer cells using biodegradable polymer nanoplexes. Biomater Sci. 2014;2(7):1007\u201315.","journal-title":"Biomater Sci"},{"issue":"11","key":"1111_CR89","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.21873\/anticanres.12983","volume":"38","author":"S Fu","year":"2018","unstructured":"Fu S, Lin J. Blocking interleukin-6 and interleukin-8 signaling inhibits cell viability, colony-forming activity, and cell migration in human triple-negative breast cancer and pancreatic cancer cells. Anticancer Res. 2018;38(11):6271\u20139.","journal-title":"Anticancer Res"},{"issue":"1","key":"1111_CR90","first-page":"349","volume":"53","author":"S Fu","year":"2018","unstructured":"Fu S, Chen X, Lin HJ, Lin J. Inhibition of interleukin 8\/C-XC chemokine receptor 1,\/2 signaling reduces malignant features in human pancreatic cancer cells. Int J Oncol. 2018;53(1):349\u201357.","journal-title":"Int J Oncol"},{"issue":"7","key":"1111_CR91","doi-asserted-by":"publisher","first-page":"e40420","DOI":"10.1371\/journal.pone.0040420","volume":"7","author":"KS Hill","year":"2012","unstructured":"Hill KS, Gaziova I, Harrigal L, et al. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8\/CXCL8 in pancreatic cancer. PLoS ONE. 2012;7(7):e40420.","journal-title":"PLoS ONE"},{"issue":"1","key":"1111_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-09847-z","volume":"22","author":"R Tanaka","year":"2022","unstructured":"Tanaka R, Kimura K, Eguchi S, et al. Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line. BMC Cancer. 2022;22(1):1.","journal-title":"BMC Cancer"},{"key":"1111_CR93","doi-asserted-by":"publisher","first-page":"2831056","DOI":"10.1155\/2017\/2831056","volume":"2017","author":"B Hu","year":"2017","unstructured":"Hu B, Qiu-Lan H, Lei RE, Shi C, Jiang HX, Qin SY. Interleukin-9 promotes pancreatic cancer cells proliferation and migration via the miR-200a\/beta-catenin axis. Biomed Res Int. 2017;2017:2831056.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1111_CR94","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.17219\/acem\/104543","volume":"28","author":"D Lu","year":"2019","unstructured":"Lu D, Qin Q, Lei R, Hu B, Qin S. Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer. Advances in Clinical & Experimental Medicine. 2019;28(10):1285.","journal-title":"Advances in Clinical & Experimental Medicine."},{"issue":"18","key":"1111_CR95","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.7150\/jca.38062","volume":"11","author":"C Zhao","year":"2020","unstructured":"Zhao C, Pu Y, Zhang H, et al. IL10-modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition. J Cancer. 2020;11(18):5345\u201352.","journal-title":"J Cancer"},{"issue":"3","key":"1111_CR96","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.surg.2017.10.056","volume":"163","author":"RB Batchu","year":"2018","unstructured":"Batchu RB, Gruzdyn OV, Mahmud EM, et al. Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Surgery. 2018;163(3):627\u201332.","journal-title":"Surgery"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01111-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01111-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01111-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:22:14Z","timestamp":1728487334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01111-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01111-w","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"31 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}